Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Common Stock Issued

Cash raised by issuing new shares.

Xilio Therapeutics, Inc.NASDAQ: XLO

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued grows, but more slowly than its trailing trend

Q1 FY2026 common stock issued of $37.26M rose 671.8% year over year, behind the +1535.2% change in trailing-twelve-month common stock issued. Sequentially, it rose 3.9% from the prior quarter. Over 3 fiscal years it compounded at +1663.7% a year.

Context

  • Common stock issued amounted to 200.6% of revenue in FY2025, up 93.0 pp from a year earlier.
  • Common stock issued increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +671.8% toward the trailing-twelve-month pace of +1535.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.26M+3.9% QoQ
Last fiscal yearDec 2025
$87.78M+1186.1% YoY
LTMMar 2026
$120.16M+1535.2% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+671.8%——
1 year+1186.1%——
3-year CAGR+1663.7%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
87.78M USD
Year-over-year change
+1186.1%
4-year CAGR
-6.8%

Common Stock Issued vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 common stock issued of $120.16M is the 2nd largest of the 4 companies compared; the peer median is $29.95M.
  • Its year-over-year change of +1535.2% is the highest of 4, against a peer median of +148.3%.
  • Common stock issued amounts to 224.7% of revenue for XLO, versus a peer median of 0.0%.
XLO Competitors Peer median
Common Stock Issued for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OKUROnKure Therapeutics, Inc.LTM Mar 2026$146.24M +148.3%-15.8%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$120.16M +1535.2%+1663.7%224.7%
PDSBPDS Biotechnology CorporationLTM Mar 2026$29.95M +187.9%+27.3%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$0 -100.0%—0.0%
Peer median (excluding XLO) $29.95M+148.3%+5.8%0.0%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
Deferred Income Tax222K0000
Stock-Based Compensation4.96M8.42M7.38M6.43M6.94M
Change in Working Capital(11.8M)2M(1.66M)31.78M25.13M
Accounts Receivables0000(5M)
Inventory00000
Accounts Payables(2.82M)485K(2.06M)1.53M152K
Other Working Capital(8.99M)1.52M405K30.26M29.97M
Other Non-Cash Items173K224K160K3K(3.56M)
Operating Cash Flow(80.75M)(75.72M)(68.62M)(18.38M)(4.99M)
Capital Expenditures(1.1M)(1.87M)(486K)(36K)(518K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.1M)(1.87M)(486K)(36K)(518K)
Debt Repayment(110K)(85K)(6.75M)(3.38M)0
Common Stock Issued116.36M16K202K6.83M87.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(467K)0025.75M0
Financing Cash Flow260.67M(69K)(6.55M)29.2M87.78M
Effect of Forex Changes0(9K)(25K)00
Net Change in Cash178.82M(77.67M)(75.68M)10.78M82.27M
Free Cash Flow(81.85M)(77.59M)(69.11M)(18.41M)(5.51M)

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.